MEDtalk: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

Best Practice Nordic | Syys 2020 | ESMO 2020 | Onkologia ja Hematologia |

In this MEDtalk M.D. Professor of Oncology, Julie Brahmer from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University presents data from KEYNOTE-024: Pembrolizumab double the 5-year OS rate for patients with metastatic, PD-L1-positive lung cancer vs chemotherapy.